Role of the ubiquitin proteasome system in hematologic malignancies. (Q38289055)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25510280%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

review article

1 reference

title

Role of the ubiquitin proteasome system in hematologic malignancies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25510280%20AND%20SRC:MED&resulttype=core&format=json

ubiquitin-proteasome system

25 February 2020

main subject

0 references

author

Anagh Anant Sahasrabuddhe

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25510280%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Kojo Elenitoba-Johnson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25510280%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

author name string

Anagh A Sahasrabuddhe

1

1 reference

1 September 2017

Kojo S J Elenitoba-Johnson

2

1 reference

1 September 2017

1 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25510280%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

published in

Immunological Reviews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25510280%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

volume

263

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25510280%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25510280%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

page(s)

224-239

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25510280%20AND%20SRC:MED&resulttype=core&format=json

Some lessons from my work on the biochemistry of the ubiquitin system

25 February 2020

cites work

1 reference

The ubiquitin system for protein degradation and some of its roles in the control of the cell-division cycle (Nobel lecture).

21 January 2018

1 reference

Ubiquitin ligases: cell-cycle control and cancer

21 January 2018

1 reference

Ubiquitin ligases in malignant lymphoma.

21 January 2018

1 reference

21 January 2018

1 reference

Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer

21 January 2018

1 reference

The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction

21 January 2018

1 reference

Ubiquitin-mediated control of oncogene and tumor suppressor gene products

21 January 2018

1 reference

F-box protein FBXL2 targets cyclin D2 for ubiquitination and degradation to inhibit leukemic cell proliferation

21 January 2018

1 reference

21 January 2018

1 reference

A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia

21 January 2018

1 reference

Role of the F-box protein Skp2 in lymphomagenesis

21 January 2018

1 reference

The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.

21 January 2018

1 reference

FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors

21 January 2018

1 reference

Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis

21 January 2018

1 reference

Smurf2 suppresses B-cell proliferation and lymphomagenesis by mediating ubiquitination and degradation of YY1.

21 January 2018

1 reference

The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia

21 January 2018

1 reference

The ubiquitin proteasome system - implications for cell cycle control and the targeted treatment of cancer

21 January 2018

1 reference

SCF ubiquitin ligases in the maintenance of genome stability

21 January 2018

1 reference

Roles of ubiquitin signaling in transcription regulation

21 January 2018

1 reference

Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death

21 January 2018

1 reference

Roles of F-box proteins in cancer

21 January 2018

1 reference

The SCF ubiquitin ligase: insights into a molecular machine

21 January 2018

1 reference

Systematic analysis and nomenclature of mammalian F-box proteins

21 January 2018

1 reference

FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias.

21 January 2018

1 reference

The ubiquitous nature of cancer: the role of the SCF(Fbw7) complex in development and transformation

21 January 2018

1 reference

Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia

21 January 2018

1 reference

Prognostic significance of the F-box protein Skp2 expression in diffuse large B-cell lymphoma

21 January 2018

1 reference

Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors

21 January 2018

1 reference

Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis

21 January 2018

1 reference

SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27

21 January 2018

1 reference

p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells

21 January 2018

1 reference

p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27

21 January 2018

1 reference

Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins

21 January 2018

1 reference

Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase

21 January 2018

1 reference

Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation.

21 January 2018

1 reference

Skp2-mediated degradation of p27 regulates progression into mitosis

21 January 2018

1 reference

Skp2-dependent degradation of p27kip1 is essential for cell cycle progression

21 January 2018

1 reference

Regulation of the cell cycle by SCF-type ubiquitin ligases

21 January 2018

1 reference

Knockdown of Fbxo7 reveals its regulatory role in proliferation and differentiation of haematopoietic precursor cells

21 January 2018

1 reference

Expression of Fbxo7 in haematopoietic progenitor cells cooperates with p53 loss to promote lymphomagenesis.

21 January 2018

1 reference

SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma

21 January 2018

1 reference

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

21 January 2018

Cancer statistics, 2010

1 reference

21 January 2018

1 reference

FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas

21 January 2018

1 reference

The Cbl family proteins: ring leaders in regulation of cell signaling

21 January 2018

1 reference

Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases

21 January 2018

1 reference

250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies

21 January 2018

1 reference

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.

21 January 2018

1 reference

Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia

21 January 2018

1 reference

Mutations in CBL occur frequently in juvenile myelomonocytic leukemia

21 January 2018

1 reference

CBL mutations in juvenile myelomonocytic leukemia and pediatric myelodysplastic syndrome

21 January 2018

1 reference

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms

21 January 2018

1 reference

Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia

21 January 2018

1 reference

Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.

21 January 2018

1 reference

Smurf2 regulates the senescence response and suppresses tumorigenesis in mice

21 January 2018

1 reference

TRIP12 and UBR5 suppress spreading of chromatin ubiquitylation at damaged chromosomes

21 January 2018

1 reference

EDD induces cell cycle arrest by increasing p53 levels

21 January 2018

1 reference

Regulation and Role of EZH2 in Cancer

21 January 2018

1 reference

Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity

21 January 2018

1 reference

The polycomb-group gene Ezh2 is required for early mouse development

21 January 2018

1 reference

Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner

21 January 2018

1 reference

EZH2 in normal and malignant hematopoiesis

21 January 2018

1 reference

Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions

21 January 2018

1 reference

Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis.

21 January 2018

1 reference

EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation

21 January 2018

1 reference

EZH2 mutations are frequent and represent an early event in follicular lymphoma

21 January 2018

1 reference

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

21 January 2018

1 reference

Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase

21 January 2018

1 reference

Roles of BCL6 in normal and transformed germinal center B cells

21 January 2018

1 reference

The diverse roles of IRF4 in late germinal center B-cell differentiation

21 January 2018

1 reference

Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells.

21 January 2018

1 reference

The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.

21 January 2018

1 reference

BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells

21 January 2018

1 reference

Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas

21 January 2018

1 reference

Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR.

21 January 2018

1 reference

Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation

21 January 2018

1 reference

Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo

21 January 2018

1 reference

BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control.

21 January 2018

1 reference

BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci

21 January 2018

1 reference

Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma

21 January 2018

1 reference

Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas

21 January 2018

1 reference

Notch signaling: switching an oncogene to a tumor suppressor.

21 January 2018

1 reference

Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma.

21 January 2018

1 reference

The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development

21 January 2018

1 reference

Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia

21 January 2018

1 reference

A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia.

21 January 2018

1 reference

NF-κB pathways in hematological malignancies

21 January 2018

1 reference

The NF-kappaB family of transcription factors and its regulation

21 January 2018

1 reference

Deregulated NF-kappaB activity in haematological malignancies

21 January 2018

1 reference

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma

21 January 2018

1 reference

SCF-mediated degradation of p100 (NF-κB2): mechanisms and relevance in multiple myeloma

21 January 2018

1 reference

Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma

21 January 2018

1 reference

MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells

21 January 2018

1 reference

Function and regulation of protein neddylation. 'Protein modifications: beyond the usual suspects' review series

21 January 2018

1 reference

Ubiquitination and degradation of the inhibitors of NF-kappaB

21 January 2018

1 reference

Mechanism of processing of the NF-kappa B2 p100 precursor: identification of the specific polyubiquitin chain-anchoring lysine residue and analysis of the role of NEDD8-modification on the SCF(beta-TrCP) ubiquitin ligase

21 January 2018

1 reference

Dual effects of IkappaB kinase beta-mediated phosphorylation on p105 Fate: SCF(beta-TrCP)-dependent degradation and SCF(beta-TrCP)-independent processing

21 January 2018

1 reference

SCF(beta)(-TrCP) ubiquitin ligase-mediated processing of NF-kappaB p105 requires phosphorylation of its C-terminus by IkappaB kinase

21 January 2018

1 reference

c-MYC: more than just a matter of life and death

21 January 2018

1 reference

c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells

21 January 2018

1 reference

The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer

21 January 2018

1 reference

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

21 January 2018

1 reference

Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival.

21 January 2018

1 reference

Regulation of T cell function by the ubiquitin-specific protease USP9X via modulating the Carma1-Bcl10-Malt1 complex

21 January 2018

1 reference

Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I).

21 January 2018

1 reference

Identification of the familial cylindromatosis tumour-suppressor gene

21 January 2018

1 reference

Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling

21 January 2018

1 reference

Cylindromatosis and the CYLD gene: new lessons on the molecular principles of epithelial growth control.

21 January 2018

1 reference

The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia.

21 January 2018

1 reference

CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes

21 January 2018

1 reference

Deubiquitylation and regulation of the immune response

21 January 2018

1 reference

Tumor suppressor CYLD: negative regulation of NF-kappaB signaling and more

21 January 2018

1 reference

CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin

21 January 2018

1 reference

The tumor suppressor CYLD regulates entry into mitosis

21 January 2018

1 reference

CYLD coordinates with EB1 to regulate microtubule dynamics and cell migration

21 January 2018

1 reference

The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration.

21 January 2018

1 reference

A20: linking a complex regulator of ubiquitylation to immunity and human disease

21 January 2018

1 reference

TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma

21 January 2018

1 reference

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

21 January 2018

1 reference

Frequent inactivation of A20 in B-cell lymphomas

21 January 2018

1 reference

The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas.

21 January 2018

1 reference

TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas

21 January 2018

1 reference

Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma

21 January 2018

1 reference

Characteristics of A20 gene polymorphisms in T-cell acute lymphocytic leukemia

21 January 2018

1 reference

Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome.

21 January 2018

1 reference

A20 restricts wnt signaling in intestinal epithelial cells and suppresses colon carcinogenesis.

21 January 2018

1 reference

TRAF6 and A20 regulate lysine 63-linked ubiquitination of Beclin-1 to control TLR4-induced autophagy

21 January 2018

1 reference

Negative regulation of the retinoic acid-inducible gene I-induced antiviral state by the ubiquitin-editing protein A20.

21 January 2018

1 reference

A20 is a negative regulator of IFN regulatory factor 3 signaling.

21 January 2018

1 reference

A20 in inflammation and autoimmunity

21 January 2018

1 reference

Abnormally high expression of proteasomes in human leukemic cells

21 January 2018

1 reference

The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis

21 January 2018

1 reference

Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation

21 January 2018

1 reference

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

Structure and functions of the 20S and 26S proteasomes

21 January 2018

1 reference

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

21 January 2018

1 reference

Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor

21 January 2018

1 reference

NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells

21 January 2018

1 reference

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

21 January 2018

1 reference

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

21 January 2018

1 reference

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

21 January 2018

1 reference

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

21 January 2018

1 reference

Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer

21 January 2018

1 reference

A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination

21 January 2018

1 reference

Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis.

21 January 2018

1 reference

SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.

21 January 2018

1 reference

Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.

21 January 2018

1 reference

CBL mutation in chronic myelomonocytic leukemia secondary to familial platelet disorder with propensity to develop acute myeloid leukemia (FPD/AML).

21 January 2018

1 reference

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

21 January 2018

1 reference

Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia

21 January 2018

1 reference

A20: from ubiquitin editing to tumour suppression

21 January 2018

1 reference

Flt3-dependent transformation by inactivating c-Cbl mutations in AML

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/IMR.12236

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25510280%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25510280%20AND%20SRC:MED&resulttype=core&format=json